Dissolution and precipitation behavior of amorphous solid dispersions.

Amorphous solid dispersions (ASDs) are widely utilized in the pharmaceutical industry for bioavailability enhancement of low solubility drugs. The important factors governing the dissolution behavior of these systems are still far from adequately understood. As a consequence, it is of interest to investigate the behavior of these systems during the dissolution process. The purpose of this research was twofold. First, the degree of supersaturation generated upon dissolution as a function of drug-polymer composition was investigated. Second, an investigation was conducted to correlate physical behavior upon dissolution with polymer loading. Felodipine and indomethacin were selected as model drugs and hydroxypropylmethylcellulose (HPMC) and polyvinylpyrrolidone (PVP) were used to form the dispersions. Diffusion and nuclear magnetic resonance spectroscopy experiments revealed that the extent of bulk supersaturation generated on dissolution of the ASD did not depend on the drug-polymer ratio. Interestingly, the maximum supersaturation generated was similar to the predicted amorphous solubility advantage. However, dynamic light scattering measurements revealed that particles on the submicron scale were generated during dissolution of the solid dispersions containing 90% polymer, whereas solid dispersions at a 50% polymer loading did not yield these nanoparticles. The nanoparticles were found to result in anomalous concentration measurements when using in situ ultraviolet spectroscopy. The supersaturation generated upon dissolution of the solid dispersions was maintained for biologically relevant timeframes for the HPMC dispersions, whereas PVP appeared to be a less effective crystallization inhibitor.

[1]  Lynne S Taylor,et al.  Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. , 2006, Journal of pharmaceutical sciences.

[2]  Lieven Baert,et al.  Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion--Part I. , 2003, International journal of pharmaceutics.

[3]  Peter York,et al.  Mechanisms of dissolution of frusemide pvp solid dispersions , 1987 .

[4]  B. Pack,et al.  Technical Evaluation of a Fiber-Optic Probe Dissolution System , 2008 .

[5]  W. Steen.  Absorption and Scattering of Light by Small Particles , 1999 .

[6]  J. Hoffman.  Thermodynamic Driving Force in Nucleation and Growth Processes , 1958 .

[7]  Bruno C. Hancock,et al.  What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.

[8]  L. S. Taylor,et al.  Analysis of the moisture sorption behavior of amorphous drug–polymer blends , 2010 .

[9]  Tahseen Mirza,et al.  Comprehensive validation scheme for in situ fiber optics dissolution method for pharmaceutical drug product testing. , 2009, Journal of pharmaceutical sciences.

[10]  O. Corrigan.  Mechanisms of Dissolution of Fast Release Solid Dispersions , 1985 .

[11]  Ping Gao,et al.  Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. , 2008, Molecular pharmaceutics.

[12]  O. Corrigan,et al.  Mechanism of drug dissolution rate enhancement from beta-cyclodextrin-drug systems. , 1982, The Journal of pharmacy and pharmacology.

[13]  J. G. Wijmans,et al.  The solution-diffusion model: a review , 1995 .

[14]  A. Serajuddin,et al.  Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. , 1999, Journal of pharmaceutical sciences.

[15]  Carl V. Thompson,et al.  On the approximation of the free energy change on crystallization , 1979 .

[16]  K. Johnston,et al.  Supersaturation Produces High Bioavailability of Amorphous Danazol Particles Formed by Evaporative Precipitation into Aqueous Solution and Spray Freezing into Liquid Technologies , 2006, Drug development and industrial pharmacy.

[17]  I. Sugimoto,et al.  Supersaturation mechanism of drugs from solid dispersions with enteric coating agents. , 1988, Chemical & pharmaceutical bulletin.

[18]  W. Higuchi,et al.  Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. , 1969, Journal of pharmaceutical sciences.

[19]  U. Holzgrabe.  Quantitative NMR spectroscopy in pharmaceutical applications. , 2010, Progress in nuclear magnetic resonance spectroscopy.

[20]  F. Csempesz,et al.  Influence of the chain composition on the thermodynamic properties of binary and ternary polymer solutions. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[21]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  D. Law,et al.  Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. , 2004, Journal of pharmaceutical sciences.

[23]  O. Corrigan,et al.  Mechanism of drug dissolution rate enhancement from β‐cyclodextrin‐drug systems , 1982 .

[24]  Lynne S. Taylor,et al.  Influence of Particle Size on the Ultraviolet Spectrum of Particulate-Containing Solutions: Implications for In-Situ Concentration Monitoring Using UV/Vis Fiber-Optic Probes , 2011, Pharmaceutical Research.

[25]  M. Ulmschneider,et al.  Thoughts on Fiber Optics in Dissolution Testing , 2001 .

[26]  G. Zografi,et al.  Water vapor absorption into amorphous sucrose-poly(vinyl pyrrolidone) and trehalose-poly(vinyl pyrrolidone) mixtures. , 2001, Journal of pharmaceutical sciences.

[27]  M. A. Farvar,et al.  Drug membrane transport enhancement using high energy drug polyvinylpyrrolidone (PVP) co-precipitates , 1980 .

[28]  K. Johnston,et al.  Highly supersaturated solutions of amorphous drugs approaching predictions from configurational thermodynamic properties. , 2008, The journal of physical chemistry. B.

[29]  Å. Rasmuson,et al.  Determination of the activity of a molecular solute in saturated solution , 2008 .

[30]  Bruno C. Hancock,et al.  Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. , 1995, Journal of pharmaceutical sciences.

[31]  Patrick J. Marsac,et al.  Estimation of Drug–Polymer Miscibility and Solubility in Amorphous Solid Dispersions Using Experimentally Determined Interaction Parameters , 2008, Pharmaceutical Research.

[32]  K. Bynum,et al.  Analytical Performance of a Fiber Optic Probe Dissolution System , 2001 .

[33]  Patrick J. Marsac,et al.  Theoretical and Practical Approaches for Prediction of Drug–Polymer Miscibility and Solubility , 2006, Pharmaceutical Research.

[34]  D. Craig,et al.  The mechanisms of drug release from solid dispersions in water-soluble polymers. , 2002, International journal of pharmaceutics.

[35]  P. Flory.  Principles of polymer chemistry , 1953 .

[36]  Raj Rajagopalan,et al.  Principles of Colloid and Surface Chemistry, Revised and Expanded , 1997 .

[37]  O. Corrigan,et al.  Retardation of Polymeric Carrier Dissolution by Dispersed Drugs: Factors Influencing the Dissolution of Solid Dispersions Containing Polyethlene Glycols , 1986 .

[38]  Ravi M Shanker,et al.  Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. , 2010, Journal of pharmaceutical sciences.

[39]  Lynne S. Taylor,et al.  Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions , 1997, Pharmaceutical Research.

[40]  W I Higuchi,et al.  Dissolution rates of high energy sulfathiazole--povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies. , 1976, Journal of pharmaceutical sciences.

[41]  Patrick J. Marsac,et al.  A Comparison of the Physical Stability of Amorphous Felodipine and Nifedipine Systems , 2006, Pharmaceutical Research.

[42]  Wei Yang,et al.  Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. , 2008, Molecular pharmaceutics.

[43]  K. Marsh,et al.  Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. , 2004, International journal of pharmaceutics.

[44]  Lian Yu,et al.  Solubility of Small-Molecule Crystals in Polymers: d-Mannitol in PVP, Indomethacin in PVP/VA, and Nifedipine in PVP/VA , 2009, Pharmaceutical Research.

[45]  Rakesh Patel,et al.  Preparation, Characterization, and Dissolution Behavior of a Solid Dispersion of Simvastatin with Polyethylene Glycol 4000 and Polyvinylpyrrolidone K30 , 2008 .

[46]  Lynne S. Taylor,et al.  Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution , 2010, Pharmaceutical Research.

[47]  Ravi M Shanker,et al.  Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement , 2011, Pharmaceutical development and technology.

[48]  Lynne S Taylor,et al.  Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[49]  Arvind K. Bansal,et al.  Stability and Solubility of Celecoxib-PVP Amorphous Dispersions: A Molecular Perspective , 2004, Pharmaceutical Research.